These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 3952612)

  • 1. Assessment of survival rates with metastatic malignant melanomas.
    Goldman LI; Elder D; Clark WH; Mastrangelo MJ; Stennett J
    Surg Gynecol Obstet; 1986 Mar; 162(3):199-203. PubMed ID: 3952612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
    Kretschmer L; Helmbold P; Emmert S; Marsch WC
    Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
    Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
    J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
    Richtig E; Ludwig R; Kerl H; Smolle J
    Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
    Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
    Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
    Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Late metastasis in malignant melanoma of the skin].
    Landthaler M; Braun-Falco O; Schlamminger F; Schubert-Fritschle G
    Dtsch Med Wochenschr; 1989 Jul; 114(30):1149-52. PubMed ID: 2752919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis and treatment of malignant melanoma of the skin (a lecture)].
    Denisov LE; Kurdina MI
    Khirurgiia (Mosk); 1996; (1):17-22. PubMed ID: 8683912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors.
    Brand CU; Ellwanger U; Stroebel W; Meier F; Schlagenhauff B; Rassner G; Garbe C
    Cancer; 1997 Jun; 79(12):2345-53. PubMed ID: 9191522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variates of survival in metastatic uveal melanoma.
    Rietschel P; Panageas KS; Hanlon C; Patel A; Abramson DH; Chapman PB
    J Clin Oncol; 2005 Nov; 23(31):8076-80. PubMed ID: 16258106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathomorphosis of metastatic malignant melanoma of the skin as effected by preoperative endolymphatic polychemotherapy].
    Naleskina LA; Tolstopiatov BA; Korovin SI
    Klin Khir (1962); 1993; (5):27-30. PubMed ID: 7933857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of adjuvant therapy with the preparation Poly-a Poly-u in patients with malignant melanoma during a 10-year observation].
    Pawlicki M; Jońca M; Krzemieniecki K; Zuchowska-Vogelgesang B
    Wiad Lek; 1993 Dec; 46(23-24):912-4. PubMed ID: 7900387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Survival analysis in patients with cutaneous malignant melanoma].
    Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
    Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
    Rudolf Z; Strojan P
    Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.
    Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim K; Hwu WJ; McIntyre S; Hwu P
    Cancer Invest; 2008 Jul; 26(6):624-33. PubMed ID: 18584354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of malignant melanoma.
    Kroon BB; Nieweg OE
    Ann Chir Gynaecol; 2000; 89(3):242-50. PubMed ID: 11079795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined treatment of patients with metastases of skin melanoma using cryotherapy].
    Iavorskiĭ VV; Karaseva VV; Tokareva ZI
    Vopr Onkol; 1988; 34(7):799-803. PubMed ID: 3420821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.